⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Certara and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Certara
↗Princeton, New Jersey, USA
Certara is a global leader in biosimulation software and technology-driven drug development services. The company provides a platform that integrates modeling, simulation, regulatory science, and evidence-generation tools to help pharmaceutical and biotechnology companies accelerate drug discovery and development, reduce clinical trial costs, and improve regulatory success rates.
Certara operates a hybrid business model, combining recurring revenue from its proprietary software (such as Phoenix PK/PD and Simcyp) with high-value scientific consulting services. The company serves over 2,300 biopharmaceutical organizations, academic institutions, and regulatory agencies worldwide, playing a critical role in the drug development lifecycle from discovery to commercialization.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Biosimulation and Drug Development Consulting
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$400M-$420M
Founded:2008
Ownership:public
Status:operating
FUNDING
Investors:EQT
STOCK
Exchange:NASDAQ
Ticker:CERT
Market Cap:$0.82B
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Small molecule, mAb, ADC, Cell therapy, Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Simcyp, Pharsight, Pinnacle 21, ChemAxon
Key Partnerships:Global regulatory agencies (FDA, EMA, PMDA), 250+ Academic institutions
COMPETITION
Position:Leader
Competitors:Cartography Biosciences, TOLREMO therapeutics, Pharmacelera
LEADERSHIP
Key Executives:
Edmundo Muniz - CEO
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Certara. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.